about
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseThe ageing systemic milieu negatively regulates neurogenesis and cognitive function.Imaging markers for Alzheimer disease: which vs howRarity of the Alzheimer disease-protective APP A673T variant in the United StatesApolipoprotein E genotype and Alzheimer's disease.Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.Inferring Social Nature of Conversations from Words: Experiments on a Corpus of Everyday Telephone Conversations.Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions.Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.Genetic and clinical features of progranulin-associated frontotemporal lobar degenerationGBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology.Magnetic resonance approaches to brain aging and Alzheimer disease-associated neuropathology.The exploration & forensic analysis of computer usage data in the elderly.Associations between observed in-home behaviors and self-reported low mood in community-dwelling older adultsPredictors of normal and successful aging among urban-dwelling elderly Brazilians.A systematic review of clinician and staff views on the acceptability of incorporating remote monitoring technology into primary care.Assessment of cognition in mild cognitive impairment: a comparative studyKernels for longitudinal data with variable sequence length and sampling intervals.Unobtrusive and ubiquitous in-home monitoring: a methodology for continuous assessment of gait velocity in elders.Medication adherence in healthy elders: small cognitive changes make a big difference.An electronic pillbox for continuous monitoring of medication adherence.Using the Guttman scale to define and estimate measurement error in items over time: the case of cognitive decline and the meaning of "points lost".Vitamin E and donepezil for the treatment of mild cognitive impairment.Comparisons of plasma/serum micronutrients between Okinawan and Oregonian elders: a pilot study.Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment-Part 2Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer diseaseOn the Disambiguation of Passively Measured In-home Gait Velocities from Multi-person Smart HomesAberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease.The FAS gene, brain volume, and disease progression in Alzheimer's diseasePhysical activity and the risk of dementia in oldest old.Microcephaly genes and risk of late-onset Alzheimer disease.Regularity and predictability of human mobility in personal space.Symptoms of sleep disturbance in persons with Alzheimer's disease and normal elderlyModeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome.Ecology of the aging human brainA simple method to rule out dementia with temporal orientation.Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging.Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans.Neuroimaging and cognition in Parkinson's disease dementia.Exceptional brain aging in a rural population-based cohort.
P50
Q24595802-72CB8ECC-0093-4F8B-8663-623F83B38C5DQ24599219-10BFB4A6-CCAE-4C4F-934B-E0B286E06246Q27001254-C3C49A23-7B3C-4B39-9316-82735CF799B6Q27346292-AC97417A-F36C-433C-877A-4535E7124650Q28249303-B6AB5718-4288-40A8-96F0-FE621D33711AQ28943325-54E3C7A5-F1EB-4DAA-B37E-9352F7301E13Q30421660-2996DDEC-49EB-4F32-8AF3-B30BE2C0B592Q30434949-EDD60E9A-B14B-467F-97E1-B6E822B25DF9Q30489052-143814C9-F572-4DD6-8465-1EA9ACEC3C71Q30503638-B0D975FD-703F-4E55-B4BC-A05714958B1FQ30527838-E8645A25-032F-488C-9A1E-E83280DCDB90Q33262847-2EE28232-04D6-4ED2-B4FB-3165056B1948Q33517306-5BBB3A3A-8781-4B08-8508-D89221E197F0Q33555424-0A69BD71-D76F-4283-93DE-2E13B909E463Q33567680-FDCC9D59-40C2-43B1-B05A-B96DE76D75ACQ33571723-69995C28-C313-488B-85C5-D29E13FDA1C0Q33703851-13CCA079-3F29-4079-9456-D5BAF9AD61FAQ33932008-B41F0F42-FB66-4BFB-BDD4-8C427B41EF3BQ33952725-4C3DCE12-C0F4-4B12-B62C-C055FD5BDF34Q34022074-B26F0F84-8627-4093-A335-A1C98D74596EQ34025827-62B58AF7-9899-49B3-8AD7-FD1A6AE81430Q34169877-9DC7DE4C-2B44-4C72-8292-54551C80CB81Q34411313-A67C00D3-631C-4722-9410-C9DFDD4CB39EQ34541938-25B26C89-4C07-4508-A7A2-6F979B52D0FDQ34551727-CB503297-7926-48CE-B589-56670F3B6A3DQ34620948-535B02E5-70F9-4ED7-8564-0823DB7F35E3Q34976920-B28927E7-7567-40E3-9095-36AF4EE61B43Q34989710-B7006AA1-C016-4849-B036-00CAB86A767EQ35001983-E18DAEC0-FF36-4ABC-AA58-8BE884D87CF4Q35033143-34C1544F-839F-49E5-BFD3-346033FAC260Q35106028-271EA900-D645-4C62-970D-D89EB94F4E14Q35108897-D5DDF8E9-54C4-4006-90D8-08BE50291D4AQ35211973-1505462E-0F98-4570-9A39-4DA211C2836CQ35497573-4D6EE4CB-3DAC-4363-B60A-9C8461711528Q35556875-D8FBD049-183A-4164-82D3-E70B44004F32Q35570896-C82F7494-9550-4671-BDF4-2AE97D6A9429Q35758666-ED65337B-60FD-4CCD-8FCC-442058A203F3Q35844926-308B0BC1-A219-4CEB-A545-73C525810510Q35891782-4D536FBB-62FB-470A-AB92-9F599A981378Q35976797-4D89C44D-B21B-42D5-86F5-ABED2C12A320
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Jeffrey Kaye
@ast
Jeffrey Kaye
@en
Jeffrey Kaye
@es
Jeffrey Kaye
@nl
Jeffrey Kaye
@sl
type
label
Jeffrey Kaye
@ast
Jeffrey Kaye
@en
Jeffrey Kaye
@es
Jeffrey Kaye
@nl
Jeffrey Kaye
@sl
altLabel
Jeffrey A Kaye
@en
prefLabel
Jeffrey Kaye
@ast
Jeffrey Kaye
@en
Jeffrey Kaye
@es
Jeffrey Kaye
@nl
Jeffrey Kaye
@sl
P214
P244
P106
P1153
35351332100
P21
P214
P244
no00021335
P31
P496
0000-0002-9971-3478
P735
P7859
lccn-no00021335